News

  • 25 September 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period ending 30 June 2019, prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union, and an outlook for the remainder of the year.

  • 25 September 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the North American pivotal study (POSEIDON) of the alfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis. The POSEIDON study intends to support marketing approval and reimbursement of the alfapump in the U.S. and Canada.

  • 19 September 2019

    Genkyotex (Euronext Paris & Brussels: FR00013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces its consolidated financial results for the six months ended June 30, 2019, prepared in accordance with IFRS. 2019 half-year condensed consolidated financial statements were subject to a limited review by the Company’s statutory auditors. A summary of 2019 half-year condensed consolidated financial statements is included in this press release, and the 2019 half-year financial report is available in the Investors section of Genkyotex’s website (in French). Genkyotex's cash and cash equivalents amounted to €4.5 million on June 30, 2019. 

  • 19 September 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Javed Butler, Dr. Maria Rosa Costanzo, Dr. Wilson Tang and Dr. Jeffrey Testani as the Company’s Heart Failure Scientific Advisors.

  • 17 September 2019

    Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code.